Regeneron Pharmaceuticals Inc (REGN)

Investment Committee Summary

Investment Thesis

At $828 (25 August 2026) on roughly 19x forward earnings, the market is pricing Regeneron's loss-of-exclusivity and drug-pricing exposure as a manageable plateau rather than as a structural earnings decline. The engine disagrees on degree rather than direction. Its base path holds the top line broadly flat to modestly growing at an operating margin near 36%, with Dupixent and the conversion of the anti-VEGF franchise to EYLEA-HD offsetting erosion in the legacy presentation. That base remains the modal outcome, but the two downside legs together carry a material minority of the weight, and the structural leg, patent cliff plus negotiated-pricing erosion, targets a level below the 52-week low. Triangulated fair value lands at $605, leaving the shares trading rich to that anchor at a gap of -27%, with a probability-weighted expected value of $617 and a twelve-month target of $625; the rating is SELL. The balance sheet is close to unlevered at net cash of ~$0.3B and stock compensation runs near 6.7% of revenue, so this equity is entirely a bet on the earnings base rather than on the capital structure. The single most damaging risk is that biosimilar competition compresses anti-VEGF volume and price faster than EYLEA-HD and Dupixent can offset, collapsing the margin the base case depends upon.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($828) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear leg carrying the most weight is the patent cliff, and its mechanism is concrete. EYLEA anti-VEGF is the profit centre, and biosimilar entry plus Vabysmo share gains attack it on price and volume simultaneously. Negotiated-pricing erosion adds a second, non-cyclical leg that does not recover with the cycle or with a better launch. In that path revenue contracts outright, the operating margin falls well below the 36% the base assumes because launch and trial spend persists against a shrinking base, and the multiple compresses as the market reprices Regeneron from a pipeline story to an ex-growth franchise. Earnings and the multiple fall together, which is how the structural target lands below the 52-week low. The falsifier is conversion: if patients do not migrate to EYLEA-HD at the rate the base assumes, this is not a soft patch but a re-rating.

Key Debate

P/E Multiple explains 80% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 15.6× consensus forward EPS, vs the house DCF terminal 12.0×, and a peer median 16.2×. The house DCF sits 26% below spot, so the market is pricing in more than the house case — roughly 3.0pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($274) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($1,084); the probability-weighted blend (PWEV $617) is -26% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 6.7% of revenue; free cash flow net of SBC is $3.09B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $274). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Pipeline Setback / Pricing Pressure (17%, $481). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising.
• Base — Pipeline Offsets LOE (35%, $631). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns.
• Growth — Launch / Indication Expansion (20%, $864). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $1,084). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $561 and 13% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (80% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 12.0x terminal FCF multiple → $615. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $983; the peer-median forward P/E is 16.2x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 68% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 14.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 17.2× (simple median 16.2×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $516–$841, centre $659 (-20% vs spot); spot sits at the 96th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $1,084.

Company Overview & Business Model

Regeneron Pharmaceuticals Inc — HEALTHCARE · BIOTECHNOLOGY. Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

How it makes money.

Edge. Wide moat — The moat is a genuine R&D-engine moat — the VelociSuite/genetics platform, the Sanofi antibody-collaboration franchise (Dupixent), and IP/regulatory exclusivity on approved biologics — that has repeatedly produced blockbusters, which supports a mid-teens terminal multiple above a generic-pharma level. But the moat is asset-specific and time-limited: if EYLEA-HD conversion stalls and biosimilars plus Vabysmo take both price and volume while the pipeline fails to deliver a new pillar, the wide-moat premium is unearned and the terminal multiple should compress from ~14x toward the ~9.5x structural level.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 110% — cash-backed.

Competitive Moat

Moat sources:

• VelociSuite / VelocImmune antibody-discovery platform and human-genetics database (repeatable R&D productivity)
• Dupixent franchise via the Sanofi collaboration (multi-indication, high-growth immunology annuity)
• Patent + regulatory exclusivity on approved biologics and manufacturing know-how (biologics are hard to copy)
• Deep late-stage pipeline (oncology bispecifics, obesity, Factor XI) as optionality beyond EYLEA/Dupixent

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.60 vs analyst floor +0.00 → delta +0.60 (n=27 mgmt / 11 Q&A; 88th pctile across the S&P book, z +1.2).

Flag: ELEVATED — management unusually upbeat vs the analyst floor relative to peers (disconfirmation watch).

News (last 365d, 1528 articles): avg ticker sentiment +0.12 (bullish 22% / bearish 12%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-01 (~38d) — IRA drug-price-negotiation selection / Medicare price-applicability checkpoint (authored)
• 2026-12-10 (~108d) — Pivotal late-stage readout (oncology bispecific / obesity / Factor XI) (authored)
• 2027-02-04 (~164d) — FY2026 results + EYLEA-HD vs biosimilar/Vabysmo share and Dupixent growth (authored)

Forecast Track Record

• EPS surprise: beat 88% of the last 8 quarters; average surprise +19.5%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 8%; mean predicted -11.5% vs realised +17.4%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• EYLEA franchise (incl. HD) net US revenue, YoY < -0.1 (2 consecutive prints). EYLEA HD is the cash engine defending the LOE. A double-digit YoY decline across two quarters signals biosimilar and Vabysmo share loss is outrunning the HD conversion, validating the erosion mechanism.
• Dupixent global net sales, YoY < 0.08 (2 consecutive prints). Dupixent is the offset to EYLEA maturity. Growth decelerating below high-single-digits for two prints removes the pillar the base case leans on and shifts weight to the setback path.
• Consolidated non-GAAP operating margin < 0.32 (2 consecutive prints). Margin midway between base (0.357) and the setback path (0.32). Two prints below signals pricing erosion and launch-spend drag are compressing profitability toward the bear structure, not a one-off.
• Pivotal pipeline readout (oncology/obesity/factor-XI) = trial miss or CRL (single event). The growth and bull paths price a pipeline that widens beyond EYLEA/Dupixent. A failed pivotal or complete-response letter on a lead late-stage asset removes the optionality the higher multiple depends on.
• Full-year revenue vs company guidance / consensus < -0.05 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $828; 52-week range $516–$841; engine rating SELL; house target $625 (-25%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $605 (-27% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

68.8/100 (confidence band 55.1–82.5), 89th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 70.0 → 70.0 → 69.9 → 69.7 → 69.7 → 68.8 → 68.8 → 68.8.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $617.07.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.30, vs QQQ +0.22 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Protective Put. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish/holder — hedge the position; a collar finances the put by capping upside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 43rd percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 50th percentile of its own month-end history (decile 6).
• IV term structure is in contango (longer-dated richer, slope +6.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.

IV term structure (contango, slope +6.9pp): 32-DTE 28% · 88-DTE 32% · 389-DTE 35%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Collar, Put Debit Spread. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 27.8% (moderate regime) · expected move ±6.5% (2026-09-25) · put/call OI 0.80 · ATM Δ 0.52 / Θ -0.48 / ν 0.98. Direction: SHORT/HEDGE (implied return -27.0% to triangulated fair value $605.01).

Bear Put Spread (Bearish) — Long 820 P / Short 605 P · 2027-02-19 · net debit $58.2 · max profit $156.80 · breakeven $761.80 · RoR 269.0% · max loss $58.20 · priced from the listed chain (EOD marks)

Defined-risk downside expression: the debit caps the loss, with the position gaining as the stock falls toward the lower strike — a way to act on a bearish view without shorting stock. Illustrative — no outcome is implied or guaranteed.

Protective Put (if held) (Hedge) — Long 820 P · 2027-02-19 · premium $65.45 · floor -1.0% · max loss $65.45 · priced from the listed chain (EOD marks)

Insurance for an existing holding — a known premium buys a floor while leaving the upside intact. A way to hold through a binary event or volatility with defined downside.

Protective Collar (if held) (Hedge) — Long 740 P / Short 920 C · 2027-02-19 · net $11.65 · floor -11.0% · cap +11.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -26% vs spot
• Monte Carlo median implies -32% vs spot
• DCF fair value implies -26% vs spot — but this is terminal-value sensitive (exit-multiple $615 vs Gordon $794, 29% apart), so it carries less weight
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -67% vs spot
• Net: the valuation anchor itself sits 27.0% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $20B + PV(terminal) $45B = EV $65B; + net cash $0.3B → equity $65B ÷ diluted shares $0.11B = $615/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $794/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 18% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $983 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (159.0); Terminal × ±15% (126.0); Op margin ±3pp (99.0); WACC ±1pp (49.0); Capex intensity ±15% (38.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 12×, FY+5 revenue $18B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.